Correlation Between Oxidative Stress Status and COVID-19 Severity
Correlation Between Oxidative Stress Markers and COVID-19 Severity Index
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Nooshin Dalili
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- more than 18 years old
- positive RT-PCR COVID-19
- compatible lung CT with COVID-19
Exclusion Criteria:
- not signing informed consent
- using antioxidants
- using statins
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Severe COVID
patients with positive PCR or compatible CT admitted in ICU or intubated
|
Checking oxidative stress markers and redox system status
|
|
Non-severe COVID-19
patients with positive PCR or compatible CT admitted in ward without hypoxia
|
Checking oxidative stress markers and redox system status
|
|
Healthy Controls
Healthy controls with negative IgM/IgG for COVID-19
|
Checking oxidative stress markers and redox system status
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MDA concentration
Time Frame: 2 weeks
|
MDA x 2 ULN in severe COVID
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biopterin concentration
Time Frame: 2 weeks
|
Difference between severe and controls
|
2 weeks
|
|
Neopterin rate of increase
Time Frame: 2 weeks
|
Difference between severe and controls
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dalili, SBMU
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SBMU.12543
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.